Nurix Therapeutics Inc Total Assets
Nurix Therapeutics Inc total assets. Based on the latest financial reports, Nurix Therapeutics Inc (NRIX) holds total assets worth $522.47 Million USD as of August 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see NRIX market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Nurix Therapeutics Inc (2018–2024)
Total assets of Nurix Therapeutics Inc from 2018 to 2024. This chart illustrates how Nurix Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Nurix Therapeutics Inc stock quote for real-time trading data and today's change.
Nurix Therapeutics Inc - Asset Composition Analysis
Nurix Therapeutics Inc Total Assets Breakdown (November 2024)
Nurix Therapeutics Inc total assets breakdown as of November 2024. Nurix Therapeutics Inc's total assets of $522.47 Million consist of 92.5% current assets and 7.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.4% |
| Accounts Receivable | $1.50 Million | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Nurix Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Nurix Therapeutics Inc (NRIX) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nurix Therapeutics Inc's current assets represent 92.5% of total assets in 2024, an increase from 89.6% in 2018.
- Cash Position: Cash and equivalents constituted 16.4% of total assets in 2024, down from 56.4% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Nurix Therapeutics Inc Competitors by Total Assets
Key competitors of Nurix Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Nurix Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.35 | 5.28 | 6.70 |
| Quick Ratio | 5.35 | 5.29 | 6.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $358.25 Million | $369.75 Million | $253.90 Million |
Nurix Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Nurix Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.18 |
| Latest Market Cap to Assets Ratio | 2.88 |
| Asset Growth Rate (YoY) | 88.2% |
| Total Assets | $669.34 Million |
| Market Capitalization | $1.93 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Nurix Therapeutics Inc's assets at a significant premium (2.88x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Nurix Therapeutics Inc's assets grew by 88.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Nurix Therapeutics Inc (2018–2024)
The table below shows the annual total assets of Nurix Therapeutics Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-11-30 | $669.34 Million | +88.23% |
| 2023-11-30 | $355.60 Million | -14.68% |
| 2022-11-30 | $416.76 Million | -12.59% |
| 2021-11-30 | $476.77 Million | +20.29% |
| 2020-11-30 | $396.34 Million | +799.80% |
| 2019-11-30 | $44.05 Million | -2.97% |
| 2018-11-30 | $45.40 Million | -- |
About Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-ce… Read more